Hypocalcemia Event Associated with Denosumab: A Real-World Study from FDA Adverse Event Reporting System (FAERS) Database

Overview

Journal Ther Innov Regul Sci

Specialties General Medicine
Pharmacology

Date 2024 Oct 25

PMID 39453599

Authors

Siyuan Gao

Guanhao Zheng

Zhichao He

Lishi Chen

Dengfeng Yan

Zhisheng Lai

Tingfeng Cai

Shijie Hu

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Denosumab is widely used for osteoporosis and cancer treatment. However, hypocalcemia induced by denosumab is a frequent adverse event. The objective of this study is to comprehensively investigate the safety signals and the occurrence of hypocalcemia in real-world patient cases reported through the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).

Methods: Reports from January 1, 2017 to December 31, 2021 were extracted from the FAERS. Only cases of hypocalcemia suspected to denosumab were eligible in pharmacovigilance study. Denosumab-related hypocalcemia safety signal were identified to characterize their clinical features. A safety signal for hypocalcemia was evaluated using reporting odds ratios (ROR).

Results: Among the 102,413 cases related to denosumab, 1042 cases were reported with denosumab-related hypocalcemia. The affected patients were mainly elderly (median age 70 years) and male (n = 568, 63.5%). In available data, the median onset time of 23 (range 0-1601) days. Most patients required drug interruption (n = 226, 72.9%) and can achieve a recovered-resolved state (n = 318, 62.1%). For the whole database, denosumab exhibited a safety signal for hypocalcemia (ROR = 14.09, 95% Cl 13.18, 15.06). In the sensitivity analyses, denosumab also showed a safety signal for hypocalcemia in cancer (ROR = 21.28, 95% Cl 18.79, 24.11) and osteoporosis (ROR = 9.29, 95% Cl 6.80, 12.59). Compared with bisphosphonates, denosumab still has safety signal for hypocalcemia (ROR = 1.88, 95% Cl 1.67, 2.11).

Conclusions: This pharmacovigilance database analysis indicates a high safety signal for hypocalcemia associated with denosumab, particularly in cancer patients.

References

Baron R, Ferrari S, Russell R . Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2010; 48(4):677-92. DOI: 10.1016/j.bone.2010.11.020. View

Montgomery C, Couch C, Emory C, Nicholas R . Giant Cell Tumor of Bone: Review of Current Literature, Evaluation, and Treatment Options. J Knee Surg. 2018; 32(4):331-336. DOI: 10.1055/s-0038-1675815. View

Clezardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F . Bone metastasis: mechanisms, therapies, and biomarkers. Physiol Rev. 2020; 101(3):797-855. DOI: 10.1152/physrev.00012.2019. View

Reid I, Billington E . Drug therapy for osteoporosis in older adults. Lancet. 2022; 399(10329):1080-1092. DOI: 10.1016/S0140-6736(21)02646-5. View

Cooper M, Gittoes N . Diagnosis and management of hypocalcaemia. BMJ. 2008; 336(7656):1298-302. PMC: 2413335. DOI: 10.1136/bmj.39582.589433.BE. View

Pepe J, Colangelo L, Biamonte F, Sonato C, Danese V, Cecchetti V . Diagnosis and management of hypocalcemia. Endocrine. 2020; 69(3):485-495. DOI: 10.1007/s12020-020-02324-2. View

Zhu J, Chen G, He Z, Zheng Y, Gao S, Li J . Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database. EClinicalMedicine. 2021; 37:100951. PMC: 8343267. DOI: 10.1016/j.eclinm.2021.100951. View

Gao S, He Z, Zhu J, Liang D, Zhao W, Yang S . Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System database. Pharmacoepidemiol Drug Saf. 2022; 31(11):1199-1205. DOI: 10.1002/pds.5493. View

Guo M, Liang J, Li D, Zhao Y, Xu W, Wang L . Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database. Thromb J. 2022; 20(1):12. PMC: 8898466. DOI: 10.1186/s12959-022-00369-z. View

10.

van Puijenbroek E, Bate A, Leufkens H, Lindquist M, Orre R, Egberts A . A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002; 11(1):3-10. DOI: 10.1002/pds.668. View

11.

Rothman K, Lanes S, Sacks S . The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004; 13(8):519-23. DOI: 10.1002/pds.1001. View

12.

Wan Y, Liu L, Zhang B, Wang S, Wang X, Chen K . Structural Characterization and Anti-Nonalcoholic Fatty Liver Effect of High-Sulfated Polysaccharide. Pharmaceuticals (Basel). 2023; 16(1). PMC: 9865482. DOI: 10.3390/ph16010062. View

13.

He Z, Lam K, Zhao W, Yang S, Li Y, Mo J . SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment. Acta Diabetol. 2022; 60(3):401-411. DOI: 10.1007/s00592-022-02015-6. View

14.

Daga N, Joseph F . Republished: Denosumab-induced severe hypocalcaemia in a patient with vitamin D deficiency. Drug Ther Bull. 2021; 59(9):139-143. DOI: 10.1136/dtb.2021.234508rep. View

15.

Deligiorgi M, Trafalis D . The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn. Expert Opin Drug Saf. 2020; 20(2):191-213. DOI: 10.1080/14740338.2021.1861246. View

16.

White P, Dennis M, Jones E, Weinberg J, Sarosiek S . Risk Factors for Development of Hypocalcemia in Patients With Cancer Treated With Bone-Modifying Agents. J Natl Compr Canc Netw. 2020; 18(4):420-427. DOI: 10.6004/jnccn.2019.7370. View

17.

Raman M, Middleton R, Kalra P, Green D . Estimating renal function in old people: an in-depth review. Int Urol Nephrol. 2017; 49(11):1979-1988. PMC: 5643354. DOI: 10.1007/s11255-017-1682-z. View

18.

Wood S, Petty D, Glidewell L, Raynor D . Application of prescribing recommendations in older people with reduced kidney function: a cross-sectional study in general practice. Br J Gen Pract. 2018; 68(670):e378-e387. PMC: 5916085. DOI: 10.3399/bjgp18X695993. View

19.

Thongprayoon C, Acharya P, Acharya C, Chenbhanich J, Bathini T, Boonpheng B . Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies. Osteoporos Int. 2018; 29(8):1737-1745. DOI: 10.1007/s00198-018-4533-6. View

20.

Jalleh R, Basu G, Le Leu R, Jesudason S . Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease. Case Rep Nephrol. 2018; 2018:7384763. PMC: 6241374. DOI: 10.1155/2018/7384763. View